Oral Cyclophosphamide for Lupus Glomerulonephritis: An Underused Therapeutic Option

AUTOR(ES)

McKinley, Alison

FONTE

American Society of Nephrology

RESUMO

Background and objectives: In our center, systemic lupus erythematosus nephritis is routinely treated with an oral cyclophosphamide (POCY) regimen. POCY is easy to administer and less expensive than intravenous cyclophosphamide (IVCY) as it is currently used in the United States; however, the use of POCY has declined in favor of IVCY. Our experience with POCY suggests that it is well tolerated and consistently associated with good long-term outcomes. Here we report this experience to build a case for maintaining POCY as a therapeutic option in lupus nephritis.

Documentos Relacionados

• Acute poststreptococcal glomerulonephritis: immune deposit disease.
• Crescentic glomerulonephritis: a possible complication of streptokinase treatment for myocardial infarction.
• Sex hormone modulation in systemic lupus erythematosus: still a therapeutic option?
• P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation
• Urinary tissue factor in glomerulonephritis: a potential marker of glomerular injury?